Naphthamidine Urokinase Plasminogen Activator Inhibitors with Improved Pharmacokinetic Properties

Overview

Journal Bioorg Med Chem Lett

Specialty Biochemistry

Date 2004 Dec 8

PMID 15582418

Citations 6

Authors

Milan Bruncko

William J McClellan

Michael D Wendt

Daryl R Sauer

Andrew Geyer

Christopher R Dalton

Michele A Kaminski

Moshe Weitzberg

Jane Gong

Joseph F Dellaria

Robert Mantei

Xumiao Zhao

Vicki L Nienaber

Kent Stewart

Vered Klinghofer

Jennifer Bouska

Todd W Rockway

Vincent L Giranda

Affiliations

Soon will be listed here.

Abstract

A series of non-amide-linked 6-substituted-2-naphthamidine urokinase plasminogen activator (uPA) inhibitors are described. These compounds possess excellent binding activities and selectivities with significantly improved pharmacokinetic profiles versus previously described amide-linked inhibitors.

Citing Articles

Urokinase plasminogen activator as an anti-metastasis target: inhibitor design principles, recent amiloride derivatives, and issues with human/mouse species selectivity.

El Salamouni N, Buckley B, Ranson M, Kelso M, Yu H Biophys Rev. 2022; 14(1):277-301.

PMID: 35340592 PMC: 8921380. DOI: 10.1007/s12551-021-00921-7.

Structure-Activity Studies with Bis-Amidines That Potentiate Gram-Positive Specific Antibiotics against Gram-Negative Pathogens.

Wesseling C, Slingerland C, Veraar S, Lok S, Martin N ACS Infect Dis. 2021; 7(12):3314-3335.

PMID: 34766746 PMC: 8669655. DOI: 10.1021/acsinfecdis.1c00466.

Proteolysis is the most fundamental property of malignancy and its inhibition may be used therapeutically (Review).

Wyganowska-Swiatkowska M, Tarnowski M, Murtagh D, Skrzypczak-Jankun E, Jankun J Int J Mol Med. 2018; 43(1):15-25.

PMID: 30431071 PMC: 6257838. DOI: 10.3892/ijmm.2018.3983.

6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer.

Buckley B, Aboelela A, Minaei E, Jiang L, Xu Z, Ali U J Med Chem. 2018; 61(18):8299-8320.

PMID: 30130401 PMC: 6290913. DOI: 10.1021/acs.jmedchem.8b00838.

The HMGB1 protein induces a metabolic type of tumour cell death by blocking aerobic respiration.

Gdynia G, Sauer S, Kopitz J, Fuchs D, Duglova K, Ruppert T Nat Commun. 2016; 7:10764.

PMID: 26948869 PMC: 4786644. DOI: 10.1038/ncomms10764.